EGA
SCMP

Eagle Global Advisors’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Eagle Global Advisors’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-16,820
Closed -$276K – 416
2015
Q2 		$276K Hold
16,820
– – 0.01% 299
2015
Q1 		$262K Hold
16,820
– – 0.01% 271
2014
Q4 		$240K Hold
16,820
– – 0.01% 283
2014
Q3 		$109K Buy
+16,820
New +$112K ﹤0.01% 318

Other funds holding SCMP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
RFC
Russell Frank Company Seattle, Washington $56.9B AUM 2.13% 1-Year Est. Return

Eagle Global Advisors's SCMP Position: Q3 2015 in Review

Eagle Global Advisors sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q3 2015, closing a stake of 16,820 shares — an estimated $276K sold.

Eagle Global Advisors first reported a position in SCMP in Q3 2014 and held it in 4 quarters. The position peaked at $276K in Q2 2015. 154 funds tracked by Wall St. Rank hold SCMP as of Q3 2015.

  • Eagle Global Advisors reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Eagle Global Advisors sold 16,820 Sucampo Pharmaceuticals, Inc. shares in Q3 2015, an estimated $276K.
  • Eagle Global Advisors first reported a position in Sucampo Pharmaceuticals, Inc. in Q3 2014 and held it in 4 quarters.
  • Eagle Global Advisors's Sucampo Pharmaceuticals, Inc. position peaked at $276K in Q2 2015.
  • 154 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q3 2015.

Based on Eagle Global Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.